David Polizzi
Family Medicine · Hampton, NJNPI 1356349625
Payments from drug & device makers
Across 46 payments — averaging $39.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Merck$125
- Takeda Pharmaceuticals U.S.A., Inc.$79
- Novo Nordisk$76
- AstraZeneca$63
- Lilly USA, LLC$51
- plus $164 from 8 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Consulting fees$1,25069%
- Food & beverage$57031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 2 | $1,262 |
| Merck | 11 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $79 |
| Novo Nordisk | 6 | $76 |
| AstraZeneca | 5 | $63 |
| Lilly USA, LLC | 4 | $51 |
| Daiichi Sankyo Inc. | 3 | $45 |
| Pfizer | 2 | $26 |
| Otsuka America Pharmaceutical, Inc. | 2 | $25 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| GSK | 1 | $13 |
| Aytu Biopharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$1,250
How this compares
$1,820 in reported general payments places this provider in the 75th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 46 | $47,014 |
| MounjaroTirzepatide | 41 | $45,323 |
| EliquisApixaban | 46 | $40,610 |
| OzempicSemaglutide | 19 | $39,194 |
| TrulicityDulaglutide | 27 | $32,123 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $20,701 |
| XareltoRivaroxaban | 18 | $19,983 |
| MyrbetriqMirabegron | 22 | $16,767 |
| FarxigaDapagliflozin Propanediol | 12 | $16,302 |
| RybelsusSemaglutide | 12 | $9,112 |
| OxycontinOxycodone Hcl | 11 | $8,498 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $7,824 |
| Atrovent HfaIpratropium Bromide | 12 | $5,495 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,184 |
| Testosterone | 25 | $4,647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $51 | $77,44668 claims |
| Novo NordiskOzempic, Rybelsus | $76 | $48,30631 claims |
| Boehringer IngelheimJardiance | $14 | $47,01446 claims |
| PfizerEliquis | $26 | $40,61046 claims |
| GSKBreo Ellipta, Anoro Ellipta, Incruse Ellipta | $13 | $32,45462 claims |
| Johnson & JohnsonXarelto | $1,262 | $19,98318 claims |
| AstraZenecaFarxiga | $63 | $16,30212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $79 | $5,18414 claims |
| MerckBelsomra | $125 | $4,59711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Hampton
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.